Key MessageThe prevention and optimal management of adverse events (AEs) associated with tyrosine kinase inhibitors is of increasing importance, especially given the potential for lifelong treatment. This review summarizes the toxicities associated with long-term bosutinib therapy in patients with Ph+ chronic myeloid leukemia as treatment progresses and provides strategies for managing these AEs.

Introduction
============

Bosutinib (SKI-606) is an orally active dual Src/Abl tyrosine kinase inhibitor (TKI) approved in the United States and Europe for the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) resistant or intolerant to prior therapy or for whom other TKIs are not appropriate choices \[[@mdy019-B1], [@mdy019-B2]\]. Bosutinib has demonstrated efficacy and manageable tolerability based on data from trials of bosutinib as a second-line therapy in patients with CP CML resistant or intolerant to imatinib \[[@mdy019-B3]\] and as third-/fourth-line treatment in patients with CP CML or advanced leukemias after failure of imatinib, dasatinib, and/or nilotinib therapy \[[@mdy019-B6]\]. In the frontline setting, despite an improvement in several efficacy end points, bosutinib was not superior to imatinib for inducing cytogenetic response and was associated with increased hepatotoxicity and gastrointestinal toxicity compared with imatinib \[[@mdy019-B10], [@mdy019-B11]\]. Thus, bosutinib is currently not indicated for patients newly diagnosed with CML \[[@mdy019-B10], [@mdy019-B12]\]. However, recent results from another ongoing study of frontline bosutinib (BFORE trial) are positive, demonstrating the superiority of bosutinib over imatinib for the treatment of patients newly diagnosed with CP CML \[[@mdy019-B13]\].

Bosutinib has a unique safety profile as compared with other TKIs, such as dasatinib, nilotinib, and ponatinib \[[@mdy019-B6], [@mdy019-B14]\]. In common with other TKIs, hematologic adverse events (AEs) such as myelosuppression are frequently associated with bosutinib treatment; the most common nonhematologic AEs associated with bosutinib across treatment lines are gastrointestinal, particularly diarrhea \[[@mdy019-B6]\]. These toxicities occur at different times during treatment; for example, diarrhea is commonly experienced soon after treatment initiation relative to other, less common toxicities, such as liver and cardiovascular events \[[@mdy019-B6], [@mdy019-B15]\]. Therefore, being able to characterize and manage toxicities associated with bosutinib therapy, as well as knowing when to expect these toxicities, is critical for optimizing treatment outcomes and ensuring compliance with therapy.

The prevention and optimal management of AEs over time is of increasing importance, especially given the potential for lifelong treatment with TKIs \[[@mdy019-B17], [@mdy019-B18]\], and recommendations for minimizing TKI AEs from the European LeukemiaNet working party on CML were recently updated \[[@mdy019-B19]\]. However, information regarding the timing and management of AEs associated with long-term TKI therapy is limited.

The objective of this review is to provide a summary of the toxicities associated with long-term bosutinib that may arise chronologically during therapy in patients with Ph+ CP CML as treatment progresses and to provide strategies for managing these toxicities.

Methods
=======

A PubMed search was performed for clinical studies published in the medical literature as of 29 June 2016 (see Appendix for details of the search strategy used). Articles were eligible for inclusion if they described the results of clinical trials (phases I--III) with end points focused on toxicities associated with bosutinib in patients with Ph+ CP CML resistant or intolerant to prior TKI therapy, in accordance with the current US and EU product labels \[[@mdy019-B1], [@mdy019-B2]\]. Preclinical articles, review articles, health economics outcomes research articles, meeting abstracts and conference proceedings, and articles that did not directly relate to toxicities associated with TKI therapies for patients with CML were excluded. Articles were initially reviewed for relevance according to these prespecified eligibility and exclusion criteria. The bibliographies of the identified articles were also surveyed for any relevant articles. Full-text versions of articles of interest were obtained and assessed for relevance by the authors. To ensure optimal characterization of bosutinib-associated toxicities, articles reporting toxicity data with the longest treatment duration were chosen for inclusion. Information sought included AEs (frequency, grade, time to onset, and time course), rates of treatment discontinuation due to AEs, line of therapy, and AE management strategies. Articles that provided clinical trial data on cross-intolerance between bosutinib and prior TKI treatment were also identified. Data were assessed qualitatively and are summarized descriptively.

Results
=======

A total of 18 articles were captured by the PubMed search, 7 of which reported bosutinib toxicity data from a phase I/II trial (study 200; NCT00261846) of patients with CP CML resistant or intolerant to imatinib receiving second-line bosutinib (CP 2L) \[[@mdy019-B3], [@mdy019-B15]\] and patients with CP CML resistant or intolerant to imatinib and dasatinib and/or nilotinib receiving third-/fourth-line bosutinib (CP 3L) \[[@mdy019-B6], [@mdy019-B7], [@mdy019-B9], [@mdy019-B15]\]. Another article reported bosutinib toxicity data from a similarly designed phase I/II study in patients with CP 2L and CP 3L residing in Japan \[[@mdy019-B20]\].

From these eight articles, those by Brümmendorf et al. \[[@mdy019-B5]\] and Cortes et al. \[[@mdy019-B9]\] were selected to summarize most characteristics of bosutinib-associated toxicities in patients with CP 2L and CP 3L, respectively, because they report safety data with the longest duration of follow-up \[median (range) duration: CP 2L, 43.6 (0.6--83.4) months; CP 3L, 32.7 (0.3--93.3) months; both are based on a snapshot ≥48 months after last subject's first visit (LSFV)\]. An article by Kantarjian et al. \[[@mdy019-B6]\] was selected because it provides detailed descriptions of the management of bosutinib-associated toxicities, and an article by Cortes et al. \[[@mdy019-B15]\] was selected for its comprehensive information regarding cardiac and vascular toxicities reported with bosutinib in the same study. Also included were two articles presenting data for cross-intolerance between bosutinib and prior imatinib \[[@mdy019-B3]\] and between bosutinib and prior imatinib, dasatinib, and/or nilotinib therapy \[[@mdy019-B7]\].

Eleven articles were excluded on the basis of the prespecified eligibility criteria and authors' combined assessment of relevance (five pharmacokinetic studies in healthy volunteers \[[@mdy019-B21]\], three studies in newly diagnosed patients \[[@mdy019-B6], [@mdy019-B10], [@mdy019-B26]\], one retrospective analysis of fourth-line bosutinib as part of a compassionate use program \[[@mdy019-B27]\], one study in patients with advanced leukemias \[[@mdy019-B8]\], and one article summarizing the EU conditional marketing authorization for bosutinib \[[@mdy019-B12]\]).

Bosutinib-associated toxicities in patients with CML
----------------------------------------------------

Across the CP 2L (*n* = 286) and CP 3L (*n* = 119) cohorts in the phase I/II trial of bosutinib in patients resistant/intolerant to prior imatinib and other TKIs \[[@mdy019-B5], [@mdy019-B6]\], the most commonly observed treatment-emergent adverse events (TEAEs) were gastrointestinal events; thrombocytopenia was the most common grade 3/4 TEAE and grade 3/4 laboratory abnormality (Table [1](#mdy019-T1){ref-type="table"}). The incidence of newly occurring bosutinib-associated toxicities (i.e. those not experienced by the same patient previously for those on treatment during a given year) generally decreased over time in the CP 2L (any TEAE: year 1, 99.7%; year 2, 73%; year 3, 66%; year 4, 49%) and CP 3L (any TEAE: year 1, 99%; year 2, 74%; year 3, 64%; year 4, 72%) cohorts (Figure [1](#mdy019-F1){ref-type="fig"}) \[[@mdy019-B5], [@mdy019-B9]\]. Notably, in the CP 3L cohort, pleural effusions occurred more frequently in year 4 (16%) versus years 1 (5%), 2 (12%), and 3 (3%). Increased blood creatinine (any grade) had a higher incidence in years 3 and 4 (5% each) versus years 1 (2%) and 2 (1%) in the CP 2L cohort and in year 4 (13%) versus years 1 (7%), 2 (4%), and 3 (3%) in the CP 3L cohort \[[@mdy019-B5], [@mdy019-B9]\]. However, recently published results suggest that the decline in renal function associated with long-term bosutinib treatment is reversible and similar in frequency and characteristics to that observed with long-term imatinib \[[@mdy019-B28]\]. Table 1.Toxicities (%) associated with bosutinib 500 mg once-daily treatment in patients with CP CML with resistance or intolerance to prior imatinib and other TKIs \[[@mdy019-B5], [@mdy019-B6], [@mdy019-B9]\]CP 2L[^a^](#tblfn2){ref-type="table-fn"}CP 3L[^b^](#tblfn3){ref-type="table-fn"}(*n* = 286)(*n* = 119)All GradeGrade 3/4All GradeGrade 3/4TEAEs[^c^](#tblfn4){ref-type="table-fn"} Gastrointestinal  Diarrhea8610839  Nausea461481  Vomiting374381  Abdominal pain262241  Constipation14\<1130 Musculoskeletal  Arthralgia161181  Back pain14\<1123  Extremity pain111---- Respiratory  Cough220220  Pleural effusion82175  Dyspnea121122 General/other  Rash369283  Fatigue261242  Headache190273  Pyrexia261150  Decreased appetite141131  Nasopharyngitis130120  Dizziness90150  Blood creatinine increased8\<1130  Asthenia142−--  Peripheral edema11\<1----  Hypertension72---- Hematologic[^d^](#tblfn5){ref-type="table-fn"}  Thrombocytopenia42263926  Anemia2711207  Neutropenia1692116  Leukopenia125---- Cardiac events[^e^](#tblfn6){ref-type="table-fn"}105125 Vascular events[^f^](#tblfn7){ref-type="table-fn"}8463Laboratory abnormalities Nonhematologic  Increased ALT/AST--11/−--6/3  Increased lipase--10----  Hyperglycemia--3----  Hypermagnesemia--11--13  Hyponatremia--3---- Hematologic  Anemia--14--8  Lymphopenia--15--15  Neutropenia--18--18  Thrombocytopenia--25--26Discontinuations6076 Due to AEs/toxicities2224 Due to disease progression1820[^3][^4][^5][^6][^7][^8][^9][^10]

![TEAEs over time: percentage of patients with TEAEs occurring in year 1 and newly occurring in years 2, 3, and 4 in ≥20% of patients with CP CML (both cohorts; any grade). ALT, alanine aminotransferase; CP CML, chronic phase chronic myeloid leukemia; TEAE, treatment-emergent adverse event. Denominators are the number of patients on treatment during the indicated years (note: the incidence of certain TEAEs appears higher in later years compared with previous years owing to a lower number of patients on treatment).](mdy019f1){#mdy019-F1}

In general, bosutinib-associated toxicities were of mild to moderate severity \[[@mdy019-B6]\]. Serious AEs (SAEs) were reported in a similar percentage of patients in the CP 2L (39%) and CP 3L (34%) cohorts; across cohorts, the most common SAEs were pneumonia, pleural effusion, and pyrexia \[[@mdy019-B6]\]. Forty (14%) patients in the CP 2L cohort died on study or within 30 days of the last bosutinib dose, most of whom had imatinib-resistant disease \[[@mdy019-B5]\]. The most common reasons for death were disease progression (*n* = 24) and AEs unrelated to treatment (*n* = 13; as assessed by the investigator and including AEs of disease progression and death); no deaths were reported as treatment related in the CP 2L cohort \[[@mdy019-B5]\]. In the CP 3L cohort, 26 (22%) patients died on study or within 30 days of the last dose, with disease progression (*n* = 12) and AEs unrelated to treatment (*n* = 10) also the most common reasons \[[@mdy019-B9]\]. One death in the CP 3L cohort due to lower gastrointestinal hemorrhage in the setting of grade 4 thrombocytopenia was considered to be associated with bosutinib treatment.

Among 321 CP CML patients receiving second-line nilotinib in an open-label, phase II study, 8 (2.5%) died during treatment or within 28 days of discontinuation and an additional 36 (11.2%) patients died after 28 days following treatment discontinuation \[[@mdy019-B29]\]. A low mortality rate was also reported with dasatinib as second-line treatment, with 2 (2.0%) deaths occurring among 101 CP CML patients, 1 within 30 days of the last dose and another 44 days after discontinuation \[[@mdy019-B30]\]. However, the median follow-up durations reported for these studies (both 24 months) are far shorter than that of the published analysis of second-line bosutinib (43.6 months) \[[@mdy019-B5], [@mdy019-B29], [@mdy019-B30]\]. Furthermore, the differences in study designs and patient populations complicate direct comparisons across studies.

Overall, TEAEs were managed with ≥1 dose interruption or reduction in 70% and 49% of patients, respectively; these dose modifications were relatively more frequent in the CP 2L cohort (72% and 49%) compared with the CP 3L cohort (66% and 50%) \[[@mdy019-B5], [@mdy019-B9]\]. Across both cohorts, 23% of patients discontinued bosutinib treatment owing to AEs, the most common of which were thrombocytopenia (6%), neutropenia (3%), and increased alanine aminotransferase (ALT; 2%) \[[@mdy019-B5], [@mdy019-B9]\]. In both the CP 2L and CP 3L cohorts, most discontinuations due to AEs occurred during the first year of bosutinib treatment (Figure [2](#mdy019-F2){ref-type="fig"}) \[[@mdy019-B5], [@mdy019-B9]\].

![Incidence of TEAEs resulting in treatment discontinuation in ≥1% of patients in years 1, 2, 3, and 4 by cohort. CP 2L, chronic phase, second-line treatment; CP 3L, chronic phase, third-line treatment; TEAE, treatment-emergent adverse event. Denominators are the number of patients on treatment during the specific years.](mdy019f2){#mdy019-F2}

Characteristics and management of individual toxicities commonly associated with bosutinib treatment
----------------------------------------------------------------------------------------------------

Published guidelines for dose adjustments and recommendations for managing bosutinib-associated AEs in patients with CML are summarized in Table [2](#mdy019-T2){ref-type="table"}. The clinical management and characteristics of individual toxicities established in clinical trials are summarized in Table [3](#mdy019-T3){ref-type="table"} and are discussed in the sections that follow. Table 2.Practical management strategies for adverse events during bosutinib therapy \[[@mdy019-B2], [@mdy019-B19], [@mdy019-B31]\]Adverse eventManagement strategyGastrointestinal DiarrheaGI upsetOtherAssess all patients for signs of diarrhea (onset, duration, stool composition, episode frequency) and dehydration (thirst, infrequent urination, dark urine, dry skin, fatigue, dizziness); manage using standards of care, including diet changes, antidiarrheals, antiemetics, and/or fluid replacementDiarrhea: NCI CTCAE grade 3/4 diarrhea (increase of ≥7 stools/day over baseline/pretreatment), withhold bosutinib until recovery to grade ≤1, then resume at 400 mg QDOther nonhematologic clinically significant moderate/severe toxicity: withhold bosutinib until resolution, then consider resuming at 400 mg QD and consider escalating dose to 500 mg QD, if appropriateGI upset: take bosutinib with a meal and with a large glass of waterAvoid alchohol, lactose-containing products, laxatives/stool softeners, raw fruits and vegetables, spicy or fatty foods, and caffeinePPIs should not be used because they may decrease bosutinib exposureMyelosuppression NeutropeniaThrombocytopeniaAssess patients for signs of thrombocytopenia (easy bruising, unexpected bleeding, blood in urine or stool); neutropenia (fever, infection)In all patients receiving bosutinib, perform a complete blood count weekly for the first month and then monthly thereafter or as indicated clinicallyNeutropenia: grade 3/4 neutropenia (ANC \<1 × 10^9^ L^--1^): withhold bosutinib until ANC ≥1 × 10^9^ L^--1^; resume bosutinib at same dose if recovery within 2 weeks; if \>2 weeks, upon recovery, reduce dose by 100 mg and resume treatmentThrombocytopenia: grade 3/4 thrombocytopenia (platelet count \<50 × 10^9^ L^--1^): withhold bosutinib until platelet count ≥50 × 10^9^ L^--1^; resume bosutinib at same dose if recovery within 2 weeks; if \>2 weeks, upon recovery, reduce dose by 100 mg and resume treatmentIf cytopenia recurs, discontinue bosutinib. Upon recovery, reduce bosutinib dose by an additional 100 mg and resume treatment.Growth factors can be used concomitantly for resistant neutropenia and thrombocytopeniaHepatic toxicity ALT/AST elevationAssess patients for signs of AST/ALT elevations (jaundice, dark urine)In all patients receiving bosutinib, perform monthly hepatic enzyme tests for the first 3 months of treatment and as indicated clinically. In patients with transaminase elevations, perform hepatic enzyme tests more frequentlyLiver transaminases \>5 × ULN: withhold bosutinib until ≤2.5 × ULN; resume at 400 mg QD thereafter (if recovery is \>4 weeks, discontinue bosutinib)Liver transaminase elevations ≥3 × ULN concurrent with bilirubin elevations \>2 × ULN and alkaline phosphatase \<2 × ULN (Hy's law case definition): discontinue bosutinibDermatologic RashAssess patients for skin irritation or signs of rash including red, flat blotches of varying sizeTreat with hypoallergenic moisturizing creams, topical steroids, antihistamines; in severe cases use systemic corticosteroids and/or antibioticsIf grade ≤2, continue bosutinib at current dose and begin topical or oral steroid treatment and monitor; reduce bosutinib dose or temporarily discontinue bosutinib treatment if grade \>2; resume/increase bosutinib dosing once the rash is resolved; permanently discontinue bosutinib if necessaryFluid retentionFluid retention events \[e.g. edema (pulmonary and/or peripheral); pleural and pericardial effusion\]: treat with diuretics and supportive care; interrupt, reduce dose, or discontinue bosutinib as necessaryRenal dysfunction[^a^](#tblfn9){ref-type="table-fn"}Assess patients for signs of renal dysfunction (changes in urinary frequency, polyuria, or oliguria)Monitor renal function status at baseline and during therapy, particularly for patients with preexisting renal impairment or risk factors for renal dysfunctionFor CrCL 30--50 ml/min, recommended starting dose: 400 mg/dayFor CrCL \<30 ml/min, recommended starting dose: 300 mg/day[^11][^12]Table 3.Characteristics and management of individual TEAEs \[[@mdy019-B5], [@mdy019-B9]\]DiarrheaALT/AST ElevationMyelosuppression[^a^](#tblfn11){ref-type="table-fn"}(*n* = 344)(*n* = 89)(*n* = 216)Median (range) time to first event, days CP 2L2 (1--1330)35 (3--1400)29 (1--1767) CP 3L2 (1--210)81 (8--492)26 (1--1202)Median (range) duration of an event,[^b^](#tblfn12){ref-type="table-fn"} days CP 2L1 (1--1510)26 (1--1714)15 (1--1373) CP 3L2 (1--413)15 (4--236)15 (1--769)Event management, *n* (%) Received dose reduction23 (7)17 (19)78 (36) Received dose interruption58 (17)32 (36)106 (49) Received concurrent medication231 (67)12 (13)[^c^](#tblfn13){ref-type="table-fn"}39 (18)[^d^](#tblfn14){ref-type="table-fn"} Permanent treatment discontinuation due to event[^e^](#tblfn15){ref-type="table-fn"}6/405 (1)[^f^](#tblfn16){ref-type="table-fn"}9/405 (2)[^f^](#tblfn16){ref-type="table-fn"}33/405 (8)[^13][^14][^15][^16][^17][^18]

### Gastrointestinal AEs

Management guidelines recommend that all patients receiving bosutinib should be assessed for diarrhea and signs of dehydration; the characteristics of these events, including onset, duration, stool composition, and frequency, should be monitored (Table [2](#mdy019-T2){ref-type="table"}). Nonpharmacologic management strategies include dose modification \[[@mdy019-B2], [@mdy019-B31]\]; adding fiber to the diet; and avoiding alcohol, lactose-containing products, laxatives/stool softeners, raw fruits and vegetables, spicy or fatty foods, and caffeine. Pharmacologic approaches include antidiarrheals, antiemetics, and/or fluid replacement; proton pump inhibitors should be avoided because they may decrease bosutinib exposure \[[@mdy019-B2]\].

Diarrhea was common in the CP 2L and CP 3L cohorts (86% and 83%, respectively), but the occurrence of grade 3/4 diarrhea events was generally low (10% and 9%; Table [1](#mdy019-T1){ref-type="table"}) \[[@mdy019-B5], [@mdy019-B9]\]. Other gastrointestinal TEAEs \[any grade (grade 3/4)\] reported with bosutinib included nausea \[CP 2L, 46% (1%); CP 3L, 48% (1%)\], vomiting \[37% (4%); 38% (1%)\], and abdominal pain \[26% (1%); 24% (1%)\] \[[@mdy019-B5], [@mdy019-B9]\].

Despite being the most commonly reported TEAE, diarrhea was responsible for only 1% of discontinuations across the CP 2L and CP 3L cohorts \[[@mdy019-B5], [@mdy019-B9]\]. Diarrhea typically occurred within 1 week of treatment initiation \[median (range) time to onset: CP 2L, 2 (1--1330) days; CP 3L, 2 (1--210) days\], although events were generally transient (median duration/event: CP 2L, 1 day; CP 3L, 2 days). Diarrhea management was effective, with the majority (67%) of affected patients receiving concomitant antidiarrheal medications, most commonly loperamide. Dose interruptions and dose reductions were required in 14% and 6% of patients with diarrhea, respectively.

### Liver toxicities

Management guidelines recommend that patients should be assessed for signs of hepatotoxicity, such as elevated ALT and aspartate aminotransferase (AST), based on the appearance of jaundice and/or dark or 'tea-colored' urine. These patients should be monitored monthly using hepatic enzyme tests for the first 3 months of bosutinib administration (more frequently in patients with preexisting transaminase elevations) \[[@mdy019-B2]\]. There are currently no pharmacologic interventions for ALT/AST elevations, although concomitant medications, including essential phospholipids, ursodiol, steroids, S-adenosylmethionine, milk thistle extract, and glycyrrhizic acid, have been used in clinical trials \[[@mdy019-B6]\]. Hepatic toxicity management is commonly achieved using dose modification (Table [3](#mdy019-T3){ref-type="table"}).

Hepatotoxicity was more commonly observed in the CP 2L versus the CP 3L cohort, with elevated ALT/AST TEAEs (any grade) occurring in 25% and 15% of patients, respectively, and the grade 3/4 laboratory abnormality increased ALT occurring in 11% and 6% (Table [1](#mdy019-T1){ref-type="table"}) \[[@mdy019-B5], [@mdy019-B9]\]. Across the CP 2L and CP 3L cohorts, the first ALT/AST TEAEs with bosutinib occurred early after treatment initiation \[median (range) time to onset, 35 (3--1400) and 81 (8--492) days, respectively\] and events were typically transient \[median (range) event duration among patients who resumed treatment, 26 (1--1714) and 15 (4--236) days\]. Patients in these cohorts with ALT/AST TEAEs were managed with transient dose interruptions (37% and 32%, respectively), dose reductions (17% and 26%), or concomitant medications (16% and 5%). In earlier reports among patients who were rechallenged with bosutinib after dose interruption due to ALT/AST elevations, 74% did not experience further ALT/AST events or did not permanently discontinue treatment because of ALT/AST elevations \[[@mdy019-B6]\].

### Cardiac and vascular AEs

Overall, cardiac toxicities were infrequent with bosutinib and occurred mostly in patients with preexisting cardiac conditions \[[@mdy019-B15]\]. In a comprehensive analysis of cardiac and vascular toxicities among all patients enrolled in the phase I/II study \[including 167 patients with advanced-phase leukemia (AP CML, BP CML, or acute lymphoblastic leukemia)\], the overall incidence of cardiac TEAEs (any grade) was 10% (grade ≥3, 5%); serious cardiac TEAEs occurred in 4% of patients, most commonly congestive cardiac failure and atrial fibrillation (1.0% each) \[[@mdy019-B15]\]. The incidence of cardiac events was similar in the CP 2L (any grade, 10%; grade 3/4, 5%) and CP 3L (12%; 5%) cohorts (unpublished data). Overall, five patients in the phase I/II study discontinued bosutinib because of cardiac toxicity, and three deaths occurred owing to cardiac TEAEs \[cardiac failure (*n* = 1) and congestive cardiac failure (*n* = 2)\]; none of these were considered treatment related. Most events occurred during the first year of treatment \[median (range) time to first event: 91 (1--2229) days\] and were of short duration \[median (range) cumulative duration: 8 (1--706) days\]. Cardiac TEAEs were managed with dose interruption in 12 (20%) patients, among whom 10 were rechallenged with bosutinib, 9 successfully. Other management strategies included dose reduction (5%) or concomitant medication (47%).

Across all cohorts, including patients with advanced leukemias, the occurrence of vascular TEAEs (any grade) was 8% (grade ≥3, 5%), of which 1% were considered treatment related \[[@mdy019-B15]\]. Vascular TEAEs occurred in 8% of CP 2L patients and 6% of CP 3L patients with the incidence of grade 3/4 events being similar in both cohorts (4% and 3%, respectively) (unpublished data). Five patients discontinued bosutinib because of vascular toxicity, and nine deaths due to vascular TEAEs were reported, seven of which occurred in patients with advanced disease. Of the nine deaths, one was considered probably related to bosutinib treatment (myocardial infarction in a patient with AP CML). The median (range) time to first vascular event was 327 (8--2452) days, and most events were of short duration \[median (range) cumulative duration: 9 (1--318) days\]. Vascular TEAEs were managed with concomitant medication in 15 (34%) patients. Of the six (14%) patients who experienced dose interruptions because of vascular toxicity, all were rechallenged successfully; one additional patient had a dose reduction.

### Other toxicities

Management strategies for other toxicities associated with bosutinib treatment include the use of antiemetics for nausea and vomiting and the use of hypoallergenic moisturizing creams, topical/systemic steroids, and antihistamines for rash (Table [3](#mdy019-T3){ref-type="table"}) \[[@mdy019-B2], [@mdy019-B31]\]. Myelosuppression should be monitored in patients receiving bosutinib based on signs of easy bruising, unexpected bleeding, and blood in urine or stool. Complete blood counts should be assessed in all patients weekly for the first month and then monthly thereafter or as indicated clinically.

Nonhematologic TEAEs (any grade) reported in the phase I/II trial of bosutinib also included fatigue (CP 2L, 25%; CP 3L, 24%), rash (35%; 28%), headache (19%; 27%), pyrexia (26%; 15%), and peripheral edema (10%; 8%), most of which were low grade \[[@mdy019-B5], [@mdy019-B9]\]. Pleural effusion was reported in 43 patients with CP CML (CP 2L, 8%; CP 3L, 17%), more commonly in patients aged ≥65 years. Among the 20 patients in the CP 3L cohort who experienced pleural effusion, all but 1 had received prior dasatinib and 14 had a medical history of these events \[[@mdy019-B9]\]. One death due to pleural effusion was reported, occurring after \>6 years on study in a patient receiving second-line bosutinib (congestive heart failure was also listed as an AE leading to death in this patient; both considered to be unrelated to treatment). Pleural effusions typically first occurred \>1 year after initiation of bosutinib treatment and were transient.

Hematologic toxicities reported in the CP 2L and CP 3L cohorts of the phase I/II trial included anemia (27% and 20%, respectively), thrombocytopenia (42% and 39%), and neutropenia (16% and 21%) \[[@mdy019-B5]\]. Hematologic TEAEs were the most common grade 3/4 events \[anemia (11% and 7%), thrombocytopenia (26% and 26%), and neutropenia (9% and 16%)\] and the most common reason for treatment discontinuation (Figure [2](#mdy019-F2){ref-type="fig"}). Myelosuppression generally first occurred early after treatment initiation and was transient.

Cross-intolerance between bosutinib and other TKIs
--------------------------------------------------

A retrospective evaluation of cross-intolerance (defined here as discontinuing bosutinib due to the same AE that led to discontinuation of a prior TKI) between second-line bosutinib and imatinib (based on a snapshot \<24 months from LSFV) found that 27% of imatinib-intolerant patients experienced the same grade 3/4 AE with bosutinib, and 6% discontinued because of the same AE \[[@mdy019-B3]\]. Similarly, a study of cross-intolerance between third-/fourth-line bosutinib and dasatinib (based on a snapshot ≥12 months from LSFV) found that 22% of dasatinib-intolerant patients experienced the same grade 3/4 AE with bosutinib, and 8% discontinued bosutinib because of the same AE \[[@mdy019-B7]\].

Among patients receiving second-line bosutinib who were intolerant to prior imatinib treatment because of myelosuppression, approximately half (*n* = 15/31) experienced grade 3/4 myelosuppression with bosutinib, with myelosuppression resulting in discontinuation of bosutinib in 13% of these patients \[[@mdy019-B3]\]. Similarly, 40% (*n* = 8/20) of patients with prior dasatinib intolerance related to myelosuppression experienced grade 3/4 myelosuppression with bosutinib when administered in the third line; 10% of these patients discontinued bosutinib owing to myelosuppression \[[@mdy019-B7]\]. Among patients with intolerance to prior imatinib therapy due to diarrhea, only one experienced grade 3/4 diarrhea with bosutinib \[[@mdy019-B3]\]. None of the patients intolerant to prior dasatinib treatment owing to diarrhea reported grade 3/4 diarrhea with bosutinib \[[@mdy019-B7]\]. Additionally, no patient with intolerance to prior imatinib \[[@mdy019-B3]\] or dasatinib \[[@mdy019-B7]\] therapy owing to nausea, vomiting, or abdominal pain experienced the same grade 3/4 AE with bosutinib. Three of 10 patients receiving second-line bosutinib with intolerance to prior imatinib treatment due to rash experienced grade 3/4 rash with bosutinib \[[@mdy019-B3]\]; however, no patient with intolerance to dasatinib due to skin disorders experienced the same grade 3/4 AE with bosutinib \[[@mdy019-B7]\]. Moreover, none of the second-line bosutinib patients with intolerance to imatinib due to edema \[[@mdy019-B3]\], fatigue \[[@mdy019-B3]\], or hepatobiliary disorders \[[@mdy019-B3]\] had cross-intolerance or experienced the same grade 3/4 AE with bosutinib. Only 2 of 19 patients with intolerance to prior dasatinib treatment due to pleural effusion experienced the same grade 3/4 AE with bosutinib, neither of whom discontinued bosutinib treatment because of pleural effusion \[[@mdy019-B7]\].

Clinical perspectives and management strategies
===============================================

To manage toxicities and facilitate adherence to bosutinib, patients should receive information on how to mitigate potential toxicities and also be asked to report all side effects at first onset, if possible. To fulfill this request, patients must be educated on the early identification of toxicities to allow for the possibility of early intervention. In addition to this, close monitoring and follow-up are required, particularly among patients with comorbidities or other risk factors. Given the risk of nonadherence with an oral cancer therapy such as bosutinib, open communication between healthcare providers and the patient is of utmost importance for prompt and appropriate management of toxicities during bosutinib treatment.

Gastrointestinal toxicities
---------------------------

Across treatment lines, gastrointestinal events (particularly diarrhea) are the most common AEs associated with bosutinib treatment. Although common, diarrhea is predominantly of low severity and is generally transient \[[@mdy019-B6], [@mdy019-B26]\]. In addition to results from clinical trials, clinical experience has shown that gastrointestinal AEs are manageable and rarely result in discontinuation of bosutinib. These events not only respond well to supportive measures, such as antiemetics and antidiarrheal medication, but also often improve spontaneously. Although dose modifications owing to these AEs are uncommon, nearly all patients who undergo dose interruption for diarrhea are successfully rechallenged with bosutinib.

To proactively address gastrointestinal side effects, it is important to inform patients that diarrhea is a common side effect of bosutinib treatment, and that it is typically transient and of low severity. Antidiarrheal medication at initiation of bosutinib treatment may be considered. Patients should be advised to report any gastrointestinal toxicity at the first sign of such events to allow for prompt initiation of the standard interventions (e.g. concomitant medication and oral hydration).

Run-in dosing with bi-weekly increases from a starting dose of 300 mg daily is currently being investigated in the German Bosutinib Dose Optimization study (BODO; EudraCT: 2014-005531-13) in CML patients receiving second-line bosutinib after failure of nilotinib or dasatinib. The Bosutinib Efficacy, Safety, Tolerability study (BEST, NCT02810990) is investigating run-in dosing of second-line bosutinib in elderly patients with CML, with a starting dose of 200 mg that is increased to 300 mg with an option to further titrate up to 400 mg, depending on molecular response. A recent report described the effects of a bosutinib dose escalation schedule on diarrhea \[[@mdy019-B32]\]. In this study, 20 patients received a starting dose of 200 mg per day followed by an increase of 100 mg every 5--7 days until a target dose of 400 or 500 mg per day was reached. With this regimen, only 40% of patients developed diarrhea and no patients experienced grade 3/4 diarrhea. Another study aimed at determining if a lower starting dose (300 mg daily) of second-line bosutinib will reduce the occurrence or severity of diarrhea and other side effects while maintaining efficacy is currently planned (NCT02906696).

Hematologic toxicities
----------------------

Myelosuppression is frequently reported within the first month of initiating bosutinib, with thrombocytopenia, anemia, and neutropenia being the most common hematologic AEs associated with bosutinib treatment and the most frequent reason for cross-intolerance. Hematologic AEs are most often managed by dose interruptions and reductions, usually successfully; most patients are able to maintain treatment adherence and few discontinue bosutinib treatment due to these events \[[@mdy019-B6]\]. Other interventions for myelosuppression include growth factor support and transfusions, when clinically indicated \[[@mdy019-B6]\].

Cardiac and vascular events
---------------------------

Cardiac and vascular AEs are of increasing concern among patients receiving TKI therapy. Notably, an increased risk of cardiovascular events has been reported with newer-generation TKIs, resulting in the implementation of additional safety measures to monitor and manage these events \[[@mdy019-B33]\]. Given the low incidence of cardiac and vascular toxicities observed with bosutinib relative to other newer-generation TKIs, bosutinib may be considered the preferable treatment option for patients with cardiac or vascular comorbidities. The most common strategy for managing cardiac AEs during bosutinib therapy is concomitant medication followed by dose interruption and dose reduction. Most patients who experience cardiac or vascular events are able to remain on bosutinib treatment.

Although bosutinib is not associated with an increased risk of cardiac or vascular AEs, healthcare providers should be aware of the potential for these events, particularly in patients with comorbidities. It is, therefore, important to perform health assessments before initiating treatment to help determine cardiac and vascular risk status and identify patients in need of closer monitoring.

Discussion
==========

Conclusions
-----------

Optimizing outcomes and ensuring compliance with bosutinib treatment requires the knowledge, close monitoring and appropriate management of AEs, along with education to alert patients to potential treatment-associated toxicities. Although there is currently an unmet need for published guidelines for monitoring and optimizing long-term compliance, current recommendations include frequent monitoring of *BCR-ABL1* gene transcript levels (three to four times per year) to improve TKI treatment adherence among patients with CML \[[@mdy019-B34]\]. A multi-team approach that involves hematologists, pharmacists, physician assistants, and nurses working closely with one another and with referring oncologists and other specialists provides patients with knowledge about their disease, treatment side-effects, and easy access for early reporting, which may enhance adherence and optimize outcomes \[[@mdy019-B35]\].
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Appendix
========

PubMed search terms used for toxicity-related articles in patients with Chronic Myeloid Leukemia:

(Chronic Myeloid Leukemia\[Title/Abstract\] OR Chronic Myelogenous Leukemia\[Title/Abstract\] OR CML\[Title/Abstract\] OR Philadelphia chromosome-positive leukemias\[Title/Abstract\]) AND bosutinib\[Title\] AND (Toxicity\[Text Word\] OR adverse events\[Text Word\] OR Safety\[Text Word\] OR Tolerability\[Text Word\]) AND English\[Language\] AND (Clinical Trial, Phase III\[Publication Type\] OR Clinical Trial, Phase II\[Publication Type\] OR Clinical Trial, Phase I\[Publication Type\] OR Clinical Trial\[Publication Type\] OR Phase III\[Title/Abstract\] OR Phase II\[Title/Abstract\] OR Phase I\[Title/Abstract\] OR Phase 3\[Title/Abstract\] OR Phase 2\[Title/Abstract\] OR Phase 1\[Title/Abstract\] OR Phase 1/2\[Title/Abstract\]) NOT Review\[Publication Type\].

[^1]: Deceased.

[^2]: H. J. Khoury and C. Gambacorti-Passerini contributed equally as senior authors.

[^3]: Dashes indicate data not reported.

[^4]: Data cutoff was 15 May 2013, with ≥48 months of follow-up from LSFV, except for cardiac and vascular events, which had a cutoff date of 23 May 2014, and an *n *=* *284.

[^5]: Data cutoff was 23 May 2014, with ≥48 months of follow-up from LSFV.

[^6]: All-cause TEAEs were reported, regardless of relation to bosutinib treatment (includes unpublished data).

[^7]: Individual hematologic TEAEs were clustered with the related terms from investigations.

[^8]: Terms used to identify cardiac events excluded the HLGT pericardial disorders and included the HLGTs cardiac arrhythmias and heart failures and all subordinate terms under the SOC cardiac disorders; the PTs cardiac death, sudden cardiac death, and sudden death under the SOC general disorders and administration site conditions; and the PTs ejection fraction decreased, electrocardiogram QT interval abnormal, and electrocardiogram QT prolonged, and long QT syndrome congenital under the SOC in investigations.

[^9]: Terms used to identify vascular events were the HLGTs coronary artery disorders, arteriosclerosis, stenosis, vascular insufficiency and necrosis, embolism and thrombosis, arterial therapeutic procedures (excluding aortic); the HLTs central nervous system hemorrhages and cerebrovascular accidents, central nervous system vascular disorders NEC, non-site specific vascular disorders NEC, peripheral vascular disorders NEC (excluding the PTs flushing and hot flash), transient cerebrovascular events, vascular imaging procedures NEC, and vascular therapeutic procedures NEC and all subordinate terms.

[^10]: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CP 2L, chronic phase, second-line treatment; CP 3L, chronic phase, third-line treatment; CP CML, chronic phase chronic myeloid leukemia; HLGT, high-level group term; HLT, high-level term; LSFV, last subject's first visit; NEC, not elsewhere classified; PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event; TKI, tyrosine kinase inhibitor.

[^11]: Classified using KDIGO based on eGFR (ml/min/1.73 m^2^): normal, ≥90; mild, 60 to \<90; mild to moderate, 45 to \<60; moderate to severe, 30 to \<45; severe, 15 to \<30; kidney failure, \<15.

[^12]: ANC, absolute neutrophil count; CrCL, creatinine clearance; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; KDIGO, Kidney Disease: Improving Global Outcomes; NCCN, National Comprehensive Cancer Network; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; PPI, proton pump inhibitor; QD, once daily; ULN, upper limit of normal.

[^13]: Myelosuppression events include anemia, hemoglobin decreased, neutropenia, neutrophil count decreased, thrombocytopenia, and platelet count decreased (includes unpublished results).

[^14]: Defined as from start to stop of event with no grade change; any change in grade represents a new event.

[^15]: Concurrent medications used for management of ALT and/or AST elevations included essential phospholipids, ursodiol, steroids, S-adenosylmethionine, milk thistle extract, and glycyrrhizic acid. Patients may have received ≥1 medication.

[^16]: Two patients received transfusion(s) and 33 patients received growth factor(s).

[^17]: Patients could report multiple TEAEs as reasons for discontinuation of treatment.

[^18]: Includes patients with no rechallenge or unsuccessful rechallenge following dose interruption, as well as those who discontinued treatment because of an event without dose interruption.
